AR036104A1 - Un receptor acoplado a la proteina g, gave3 - Google Patents
Un receptor acoplado a la proteina g, gave3Info
- Publication number
- AR036104A1 AR036104A1 ARP020102346A ARP020102346A AR036104A1 AR 036104 A1 AR036104 A1 AR 036104A1 AR P020102346 A ARP020102346 A AR P020102346A AR P020102346 A ARP020102346 A AR P020102346A AR 036104 A1 AR036104 A1 AR 036104A1
- Authority
- AR
- Argentina
- Prior art keywords
- gave3
- agonist
- isolated
- seq
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
Abstract
Un ácido nucleico aislado que comprende la secuencia de nucleótidos de GAVE3 8SEC ID NO: 1) o una variante de GAVE3. Un ácido nucleico aislado que comprende una secuencia que codifica un polipéptido GAVE3 con la secuencia de aminoácidos de SEC ID NO: 2. Un polipéptido purificado, cuya secuencia de aminoácido comprende SEC ID NO: 2. Un polipéptido purificado que comprende el tercer lazo intracelular según lo expuesto en SEC ID NO: 2. Además de proteínas de GAVE3 de longitud completa, aisladas, se describen proteínas de fusión de GAVE3 aisladas, péptidos antígenos y anticuerpos anti-GAVE3. Se describe GAVE3, vectores de expresión recombinante, células huéspedes en las que los vectores de expresión se han introducido. También se describe un método para producir una proteína, el uso de un agonista, antagonista o agonista inverso de GAVE3 o de una composición farmacéutica para la fabricación de un medicamento para modular la actividad de senalamiento de GAVE3 o la transducción de senal en un paciente que necesita de dicho tratamiento; un método para identificar un agonista o agonista inverso o antagonista de GAVE y una composición terapéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/886,041 US20030059869A1 (en) | 2001-06-22 | 2001-06-22 | Novel G protein-coupled receptor, GAVE3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036104A1 true AR036104A1 (es) | 2004-08-11 |
Family
ID=25388250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102346A AR036104A1 (es) | 2001-06-22 | 2002-06-21 | Un receptor acoplado a la proteina g, gave3 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20030059869A1 (es) |
| JP (1) | JP2005500036A (es) |
| KR (1) | KR20040022432A (es) |
| AR (1) | AR036104A1 (es) |
| BR (1) | BR0210937A (es) |
| CA (1) | CA2451686A1 (es) |
| IL (1) | IL159477A0 (es) |
| MX (1) | MXPA03011843A (es) |
| NO (1) | NO20035670L (es) |
| WO (1) | WO2003000846A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2077913T3 (pl) * | 2006-09-29 | 2013-06-28 | Basf Se | Sposób regeneracji środka pomocniczego do filtracji |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2388865A1 (en) * | 1999-11-16 | 2001-05-25 | Pharmacia & Upjohn Company | Novel g protein-coupled receptors |
-
2001
- 2001-06-22 US US09/886,041 patent/US20030059869A1/en not_active Abandoned
-
2002
- 2002-06-21 BR BRPI0210937-9A patent/BR0210937A/pt unknown
- 2002-06-21 WO PCT/US2002/019490 patent/WO2003000846A2/en not_active Application Discontinuation
- 2002-06-21 AR ARP020102346A patent/AR036104A1/es not_active Application Discontinuation
- 2002-06-21 IL IL15947702A patent/IL159477A0/xx unknown
- 2002-06-21 JP JP2003507233A patent/JP2005500036A/ja not_active Ceased
- 2002-06-21 CA CA002451686A patent/CA2451686A1/en not_active Abandoned
- 2002-06-21 MX MXPA03011843A patent/MXPA03011843A/es unknown
- 2002-06-21 KR KR10-2003-7016768A patent/KR20040022432A/ko not_active Application Discontinuation
-
2003
- 2003-12-18 NO NO20035670A patent/NO20035670L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005500036A (ja) | 2005-01-06 |
| BR0210937A (pt) | 2006-10-24 |
| MXPA03011843A (es) | 2004-03-26 |
| US20030059869A1 (en) | 2003-03-27 |
| WO2003000846A2 (en) | 2003-01-03 |
| CA2451686A1 (en) | 2003-01-03 |
| KR20040022432A (ko) | 2004-03-12 |
| IL159477A0 (en) | 2004-06-01 |
| NO20035670L (no) | 2004-02-19 |
| WO2003000846A3 (en) | 2004-03-04 |
| NO20035670D0 (no) | 2003-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rottier et al. | Predicted membrane topology of the coronavirus protein E1 | |
| DK0861261T3 (da) | Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå | |
| DK0751992T3 (da) | Karendotelvækstfaktor 2 | |
| DE69829668D1 (de) | Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe | |
| SE9004010A (sv) | Viralt medel | |
| AR062867A2 (es) | Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la | |
| NO995002D0 (no) | Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF-<alfa>-molekyler og DNA | |
| KR870009025A (ko) | 재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 방법, 표현 벡타 및 재조합 숙주 및 그의 재약상 용도 | |
| DK0813545T3 (da) | Nukleotid- og proteinsekvenser af hvirveldyrs-Serrate-gener og fremgangsmåde baseret derpå | |
| ATE182901T1 (de) | Für androgen-rezeptor-protein kodierende dna | |
| NO20025153D0 (no) | FremgangsmÕter og sammensetninger for Õ svekke formering av HIV-1 | |
| DK0479948T3 (da) | Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder | |
| ATE293169T1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
| HUP0002472A2 (hu) | Izolált dendritikus sejtmembrán-fehérje gének | |
| RU93045577A (ru) | Слитные полипептиды | |
| DE69322872D1 (de) | Vakzine gegen immunodefizienz-virus der katze (kiv) | |
| PT996726E (pt) | Proteina de membrana de celulas t (tirc7) peptidos e anticorpos dela derivados e suas utilizacoes | |
| ES2300625T3 (es) | Peptido paralizante de musaraña para uso en terapia neuromuscular. | |
| AR036104A1 (es) | Un receptor acoplado a la proteina g, gave3 | |
| RU2214273C2 (ru) | ДНК-ПОСЛЕДОВАТЕЛЬНОСТИ, КОДИРУЮЩИЕ ЧЕЛОВЕЧЕСКИЕ ПРОТЕИНЫ Tx И Ty, РОДСТВЕННЫЕ КОНВЕРГИРУЮЩЕМУ ИНТЕРЛЕЙКИН-1-β ФЕРМЕНТУ | |
| AU3982289A (en) | Insulinomimetic and insulin receptor binding site peptides | |
| WO1999042127A3 (en) | Receptor derived peptides as modulators of receptor activity | |
| WO2003014293A3 (en) | Novel polypeptide analogs and fusions and their methods of use | |
| EA200200598A1 (ru) | Генная терапия вич-инфицированных путем экспрессии заякоренных на мембране пептидов gp41 | |
| HUP0100132A2 (hu) | A béta-lipotropin és felhasználása |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |